Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Gilead Sciences Inc (GILD)

Gilead Sciences Inc (GILD)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 89,785,264
  • Shares Outstanding, K 1,253,809
  • Annual Sales, $ 24,689 M
  • Annual Income, $ 123,000 K
  • 60-Month Beta 0.39
  • Price/Sales 3.62
  • Price/Cash Flow 8.64
  • Price/Book 4.58
Trade GILD with:

Options Overview

Details
  • Implied Volatility 22.95%
  • Historical Volatility 14.93%
  • IV Percentile 24%
  • IV Rank 27.63%
  • IV High 40.33% on 01/04/21
  • IV Low 16.32% on 09/08/21
  • Put/Call Vol Ratio 3.09
  • Today's Volume 17,647
  • Volume Avg (30-Day) 17,003
  • Put/Call OI Ratio 0.68
  • Today's Open Interest 411,557
  • Open Int (30-Day) 407,663

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate 1.65
  • Number of Estimates 9
  • High Estimate 1.72
  • Low Estimate 1.47
  • Prior Year 2.11
  • Growth Rate Est. (year over year) -21.80%

Price Performance

See More
Period Period Low Period High Performance
1-Month
70.11 +2.14%
on 09/14/21
73.34 -2.36%
on 08/18/21
-1.42 (-1.94%)
since 08/17/21
3-Month
65.89 +8.68%
on 06/18/21
73.34 -2.36%
on 08/18/21
+4.39 (+6.53%)
since 06/17/21
52-Week
56.56 +26.61%
on 12/31/20
73.34 -2.36%
on 08/18/21
+6.57 (+10.10%)
since 09/17/20

Most Recent Stories

More News
Gilead to Present Latest Antiviral Research Data Addressing Urgent Global Needs in Infectious Disease at IDWeek 2021

--- Research Examines Strategies to Enhance the Participation of Communities Underrepresented in HIV Clinical Trials -

GILD : 71.61 (+0.39%)
Global Diverticulitis Drugs Market Increasing Gastrointestinal Diseases to Create Growth Opportunities for the Market till 2029

Research Nester published a report titled "" which delivers detailed overview of the global diverticulitis drugs market in terms of market segmentation by drug type, route of administration, distribution...

EMMA : 1.7300 (+9.49%)
ABT : 126.79 (-0.51%)
GSK : 38.93 (-0.46%)
ARDX : 1.3100 (-2.24%)
GILD : 71.61 (+0.39%)
PFE : 43.89 (-1.30%)
HIK.LN : 2,358.000 (-2.68%)
Lymphoproliferative Disorder Treatment Market Emerging Trends, Market Research, And Comprehensive Insights 2028

Research Nester released a report titled "" which delivers detailed overview of the global lymphoproliferative disorder treatment market in terms of market segmentation by route of administration, drug...

ATRA : 16.08 (+1.32%)
NOVN : 8.56 (+1.30%)
MRK : 71.68 (-0.40%)
BMY : 61.31 (+0.13%)
ABBV : 107.73 (-0.32%)
GILD : 71.61 (+0.39%)
AZN.LN : 8,193.000 (+1.61%)
PFE : 43.89 (-1.30%)
Trodelvy(R) Significantly Improved Quality of Life Over Standard of Care in 2L+ Metastatic Triple-Negative Breast Cancer in Phase 3 ASCENT Study

--- Trodelvy Is First Treatment to Improve Survival in Metastatic TNBC -

GILD : 71.61 (+0.39%)
New Data Demonstrate Trodelvy(R) Survival Benefit in Metastatic Triple-Negative Breast Cancer Patients Regardless of Initial HR/HER2 Status

--- Trodelvy Is the First Treatment to Demonstrate Survival Benefit in Metastatic TNBC -

GILD : 71.61 (+0.39%)
Gilead Sciences (GILD) Stock Moves 0.23%: What You Should Know

In the latest trading session, Gilead Sciences (GILD) closed at $71.15, marking a +0.23% move from the previous day.

GILD : 71.61 (+0.39%)
Gilead to Present New Data at ESMO Congress 2021 Reinforcing the Practice-changing Potential of Trodelvy

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of new research on its first-in-class antibody-drug conjugate (ADC) Trodelvy(R) (sacituzumab govitecan-hziy) at the European Society...

GILD : 71.61 (+0.39%)
Adamis (ADMP) Begins Dosing in COVID Oral Antiviral Study

Adamis (ADMP) starts dosing patients in phase II/III study to evaluate its oral investigational antiviral for the treatment of COVID-19.

PFE : 43.89 (-1.30%)
MRK : 71.68 (-0.40%)
GILD : 71.61 (+0.39%)
ADMP : 1.1000 (unch)
Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know

Gilead Sciences (GILD) closed the most recent trading day at $72.34, moving +0.65% from the previous trading session.

GILD : 71.61 (+0.39%)
Merck (MRK) Begins Molnupiravir Study for COVID Prevention

Merck (MRK) starts enrolling participants in phase III study to evaluate its oral investigational antiviral for the prevention of COVID-19.

REGN : 651.88 (-0.20%)
PFE : 43.89 (-1.30%)
MRK : 71.68 (-0.40%)
GILD : 71.61 (+0.39%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The Company strive to transform and simplify care for people with life-threatening illnesses around the world. Gilead's portfolio of products...

See More

Key Turning Points

3rd Resistance Point 73.42
2nd Resistance Point 72.59
1st Resistance Point 72.10
Last Price 71.61
1st Support Level 70.78
2nd Support Level 69.95
3rd Support Level 69.46

See More

52-Week High 73.34
Last Price 71.61
Fibonacci 61.8% 66.93
Fibonacci 50% 64.95
Fibonacci 38.2% 62.97
52-Week Low 56.56

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar